UCL and our partner institutions have multiple strengths, providing a unique foundation for studies related to antimicrobial resistance.
Close links with clinical facilities ensure that research is based on a sound understanding of clinical needs, and clinical platforms are available for testing new treatments, control strategies, and diagnostic or other tools.
UCL has strong links with UCLH and other major hospital sites, including the Royal Free Hospital, Great Ormond Street Hospital and Moorfields Eye Hospital. The UCLH/UCL National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) provides a key platform for clinical research and piloting of innovative practice, and has adopted antimicrobial resistance as one of its key themes.
Through UCLPartners - an academic health science partnership with over 40 higher education and NHS members - UCL has access to a community of 100,000 health professionals and academics, plus associated groups, who meet the health needs of some six million people.
UCL also has exceptional strengths in clinical trials, hosting a Comprehensive Clinical Trials Unit as well as the MRC Clinical Trials Unit, which is involved in several major antibiotic trials.
Through UCLPartners and other formal and informal partnerships, UCL is part of an extensive academic network of researchers working on microbial pathogens, infection and antimicrobial resistance.
Our researchers maintain multiple collaborations with colleagues at the London School of Hygiene & Tropical Medicine, at Queen Mary University of London, at the Wellcome Trust Sanger Institute, and at many other leading centres of research - in the UK and internationally.
UCL has a strong commitment to cross-disciplinary research. Researchers in the School of Life and Medical Sciences frequently collaborate with colleagues working in other disciplines, including Engineering, Computer Science and Chemistry.
Nanotechnology is a particular strength, with innovative being carried out on nano-sensors with a variety of possible uses in diagnostics and antibiotic development.
Health informatics is a further strength, with cross-disciplinary networking facilitated by the UCL Institute of Digital Health. UCL is a key partner in the Farr Institute of Health Informatics Research, London, a centre of excellence in research based on electronic health records. UCL researchers lead the Farr Institute @ London's infection workstream.
UCL is committed to working in partnership with industry. We collaborate with many small biotech companies in the UK and internationally, and have a long history of productive relationships with large pharmaceutical companies.
UCL is highly supportive of staff working in public outreach. We have a dedicated public engagement unit and provide financial support for projects and training, for students and academics.
Activities of the UCL Antimicrobial Resistance Network are overseen by a multidisciplinary steering group.
Join the UCL Antimicrobial Resistance Network
If you are a member of UCL or an institution affiliated to UCLPartners and would like to join the UCL Antimicrobial Resistance Network, contact Dr Lena Ciric, Network Coordinator.